Abstract: Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.

Abstract: A method and a system for automatic machine learning-based prediction of new energy power with cloud-edge collaboration are disclosed. The method includes: obtaining, in response to a power prediction demand for a target new energy station, future numerical weather prediction data of the target new energy station in a future period and historical output power of a historical period corresponding to the future period; selecting, based on missing of the future numerical weather prediction data and a data amount of the historical output power, a target power prediction model corresponding to the target new energy station; and adjusting the target power prediction model according to the target working mode, and predicting, by the adjusted target power prediction model, a target output power of the target new energy station in the future period, based on the future numerical weather prediction data and the historical output power.

Abstract: Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.

Abstract: The present invention relates to payloads containing functionalized platinum-(benz)acridine hybrid agents as cytotoxic warheads and a method of synthesizing the payloads. The payload can be regioselectively conjugated to a biologically active moiety in order to facilitate the delivery and/or enhance the activity of the platinum compound.

Abstract: Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.

Abstract: The present invention relates to payloads containing functionalized platinum-(benz)acridine hybrid agents as cytotoxic warheads and a method of synthesizing the payloads. The payload can be regioselectively conjugated to a biologically active moiety in order to facilitate the delivery and/or enhance the activity of the platinum compound.